Cytokines and subarachnoid hemorrhage

FNU Ruchika; Siddharth Shah; Maliya Delawan; Neupane Durga; Brandon Lucke-Wold

doi:10.59400/ivd.v3i1.55

FNU Ruchika Department of Neurosurgery, University of Florida
Siddharth Shah Department of Neurosurgery, University of Florida
Maliya Delawan Department of Neurosurgery, University of Florida
Neupane Durga Department of Neurosurgery, University of Florida
Brandon Lucke-Wold Department of Neurosurgery, University of Florida

Ariticle ID: 55

200 Views, 133 PDF Downloads

DOI: https://doi.org/10.59400/ivd.v3i1.55

Keywords: subarachnoid hemorrhage, cytokines, inflammation, TNF-α, interleukin, secondary brain injury

Abstract

Subarachnoid hemorrhage (SAH) remains a potentially devastating cerebrovascular disease with a high morbidity and mortality rate, irrespective of treatment. The disease still has a 40-50% mortality rate with a 70% rate of cerebral vasospasm in those patients. The release of cytokines has been implicated in the development and progression of SAH. In this paper, we will explore the role of cytokines in aneurysmal subarachnoid hemorrhage (aSAH), including their effects on the inflammatory response, cerebral vasospasm, blood-brain barrier disruption, and neuronal damage. We also identify the role of the glymphatic system in progression of aSAH. The review will also briefly touch upon current research on potential therapeutic targets aimed at modulating cytokine activity in patients with aSAH. This review aims to give an in-depth review of the cytokines involved in aSAH and serve as a catalyst to research directed towards treatment options for aSAH.

References

[1] Budohoski KP, Guilfoyle M, Helmy A, et al. The pathophysiology and treatment of delayed cerebral ischaemia following subarachnoid haemorrhage. Journal of Neurology, Neurosurgery & Psychiatry 2014; 85(12): 1343–1353. doi: 10.1136/jnnp-2014-307711

[2] Dodd WS, Laurent D, Dumont AS, et al. Pathophysiology of delayed cerebral ischemia after subarachnoid hemorrhage: A review. Journal of the American Heart Association 2021; 10(15): e021845. doi: 10.1161/JAHA.121.021845

[3] Stoll JR, Vaidya TS, Mori S, et al. Association of interleukin-6 and tumor necrosis factor-α with mortality in hospitalized patients with cancer. Journal of the American Academy of Dermatology 2021; 84(2): 273–282. doi: 10.1016/j.jaad.2020.03.010

[4] Kang S, Kishimoto T. Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms. Experimental & Molecular Medicine 2021; 53(7): 1116–1123. doi: 10.1038/s12276-021-00649-0

[5] Rochfort KD, Collins LE, McLoughlin A, Cummins PM. Tumour necrosis factor-α-mediated disruption of cerebrovascular endothelial barrier integrity in vitro involves the production of proinflammatory interleukin-6. Journal of Neurochemistry 2016; 136(3): 564–572. doi: 10.1111/jnc.13408

[6] Bauer AM, Rasmussen PA. Treatment of intracranial vasospasm following subarachnoid hemorrhage. Frontiers in Neurology 2014; 5: 72. doi: 10.3389/fneur.2014.00072

[7] Geraghty JR, Testai FD. Delayed cerebral ischemia after subarachnoid hemorrhage: Beyond vasospasm and towards a multifactorial pathophysiology. Current Atherosclerosis Reports 2017; 19(12): 50. doi: 10.1007/s11883-017-0690-x

[8] Dong G, Li C, Hu Q, et al. Low-dose IL-2 treatment affords protection against subarachnoid hemorrhage injury by expanding peripheral regulatory T cells. ACS Chemical Neuroscience 2021; 12(3): 430–440. doi: 10.1021/acschemneuro.0c00611

[9] Chen S, Xu PL, Fang Y, Lenahan C. The updated role of the blood brain barrier in subarachnoid hemorrhage: From basic and clinical studies. Current Neuropharmacology 2020; 18(12): 1266–1278. doi: 10.2174/1570159X18666200914161231

[10] Theofilis P, Sagris M, Oikonomou E, et al. Inflammatory mechanisms contributing to endothelial dysfunction. Biomedicines 2021; 9(7): 781. doi: 10.3390/biomedicines9070781

[11] Aoki T, Frȍsen J, Fukuda M, et al. Prostaglandin E2-EP2-NF-κB signaling in macrophages as a potential therapeutic target for intracranial aneurysms. Science Signaling 2017; 10(465): eaah6037. doi: 10.1126/scisignal.aah6037

[12] Frösen J, Cebral J, Robertson AM, Aoki T. Flow-induced, inflammation-mediated arterial wall remodeling in the formation and progression of intracranial aneurysms. Neurosurgical Focus 2019; 47(1): E21. doi: 10.3171/2019.5.focus19234

[13] Lucke-Wold BP, Logsdon AF, Manoranjan B, et al. Aneurysmal subarachnoid hemorrhage and neuroinflammation: A comprehensive review. International Journal of Molecular Sciences 2016; 17(4): 497. doi: 10.3390/ijms17040497

[14] Weiland J, Beez A, Westermaier T, et al. Neuroprotective strategies in aneurysmal subarachnoid hemorrhage (aSAH). International Journal of Molecular Sciences. 2021; 22(11): 5442. doi: 10.3390/ijms22115442

[15] Li K, Barras CD, Chandra RV, et al. A review of the management of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. World Neurosurgery 2019; 126: 513–527. doi: 10.1016/j.wneu.2019.03.083

[16] Viderman D, Tapinova K, Abdildin YG. Mechanisms of cerebral vasospasm and cerebral ischaemia in subarachnoid haemorrhage. Clinical Physiology and Functional Imaging 2023; 43(1): 1–9. doi: 10.1111/cpf.12787

[17] Al-Tamimi YZ, Bhargava D, Orsi NM, et al. Compartmentalisation of the inflammatory response following aneurysmal subarachnoid haemorrhage. Cytokine 2019; 123: 154778. doi: 10.1016/j.cyto.2019.154778

[18] Fassbender K, Hodapp B, Rossol S, et al. Inflammatory cytokines in subarachnoid haemorrhage: Association with abnormal blood flow velocities in basal cerebral arteries. Journal of Neurology, Neurosurgery & Psychiatry 2001; 70(4): 534–537. doi: 10.1136/jnnp.70.4.534

[19] Hendryk S, Jarzab B, Josko J. Increase of the IL-1 beta and IL-6 levels in CSF in patients with vasospasm following aneurysmal SAH. Neuroendocrinology Letters 2004; 25(1–2): 141–147.

[20] Jedrzejowska-Szypułka H, Larysz-Brysz M, Kukla M, et al. Neutralization of interleukin-1beta reduces vasospasm and alters cerebral blood vessel density following experimental subarachnoid hemorrhage in rats. Current Neurovascular Research 2009; 6(2): 95–103. doi: 10.2174/156720209788185669

[21] Croci DM, Sivanrupan S, Wanderer S, et al. Preclinical and clinical role of interleukin-6 in the development of delayed cerebral vasospasm and neuronal cell death after subarachnoid hemorrhage: Towards a potential target therapy? Neurosurgical Review 2022; 45(1): 395–403. doi: 10.1007/s10143-021-01628-9

[22] Osuka K, Suzuki Y, Tanazawa T, et al. Interleukin-6 and development of vasospasm after subarachnoid haemorrhage. Acta Neurochirurgica 1998; 140(9): 943–951. doi: 10.1007/s007010050197

[23] Chaudhry SR, Stoffel-Wagner B, Kinfe TM, et al. Elevated systemic IL-6 levels in patients with aneurysmal subarachnoid hemorrhage is an unspecific marker for post-SAH complications. International Journal of Molecular Sciences 2017; 18(12): 2580. doi: 10.3390/ijms18122580

[24] Liu W, Li R, Yin J, et al. Mesenchymal stem cells alleviate the early brain injury of subarachnoid hemorrhage partly by suppression of Notch1-dependent neuroinflammation: Involvement of botch. Journal of Neuroinflammation. 2019; 16: 1–20. doi: 10.1186/s12974-019-1396-5

[25] Wang Y, Zhong M, Tan XX, et al. Expression change of interleukin-8 gene in rabbit basilar artery after subarachnoid hemorrhage. Neuroscience Bulletin 2007; 23(3): 151–155. doi: 10.1007/s12264-007-0022-1

[26] Griessenauer CJ, Chua MH, Hanafy KA, et al. Soluble Fms-like tyrosine kinase 1 (sFlt-1) and risk of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. World Neurosurgery 2017; 108: 84–89. doi: 10.1016/j.wneu.2017.08.128

[27] Ahn SH, Burkett A, Paz A, et al. Systemic inflammatory markers of persistent cerebral edema after aneurysmal subarachnoid hemorrhage. Journal of Neuroinflammation 2022; 19(1): 199. doi: 10.1186/s12974-022-02564-1

[28] Vlachogiannis P, Hillered L, Enblad P, Ronne-Engström E. Temporal patterns of inflammation-related proteins measured in the cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage using multiplex proximity extension assay technology. PLoS One 2022; 17(3): e0263460. doi: 10.1371/journal.pone.0263460

[29] Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacological Reviews 2005; 57(2): 173–185. doi: 10.1124/pr.57.2.4

[30] Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: Molecular organization and role in vascular homeostasis. Physiological Reviews 2004; 84(3): 869–901. doi: 10.1152/physrev.00035.2003

[31] Walsh TG, Murphy RP, Fitzpatrick P, et al. Stabilization of brain microvascular endothelial barrier function by shear stress involves VE‐cadherin signaling leading to modulation of pTyr‐occludin levels. Journal of Cellular Physiology 2011; 226(11): 3053–3063. doi: 10.1002/jcp.22655

[32] Alves JL. Blood-brain barrier and traumatic brain injury. Journal of Neuroscience Research 2014; 92(2): 141–147. doi: 10.1002/jnr.23300

[33] Geraghty JR, Davis JL, Testai FD. Neuroinflammation and microvascular dysfunction after experimental subarachnoid hemorrhage: Emerging components of early brain injury related to outcome. Neurocritical Care 2019; 31(2): 373–389. doi: 10.1007/s12028-019-00710-x

[34] Yang C, Hawkins KE, Doré S, Candelario-Jalil E. Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke. American Journal of Physiology-Cell Physiology 2019; 316(2): C135–C153. doi: 10.1152/ajpcell.00136.2018.

[35] Zhao Y, Luo Y, Liu Y, et al. The role of autophagy and apoptosis in early brain injury after subarachnoid hemorrhage: An updated review. Molecular biology reports 2022; 49(11): 10775–10782. doi: 10.1007/s11033-022-07756-9

[36] Figiel I. Pro-inflammatory cytokine TNF-alpha as a neuroprotective agent in the brain. Acta Neurobiologiae Experimentalis 2008; 68(4): 526–534.

[37] Lopez-Ramirez MA, Fischer R, Torres-Badillo CC, et al. Role of caspases in cytokine-induced barrier breakdown in human brain endothelial cells. The Journal of Immunology 2012; 189(6): 3130–3139. doi: 10.4049/jimmunol.1103460

[38] Nishioku T, Matsumoto J, Dohgu S, et al. Tumor necrosis factor-alpha mediates the blood-brain barrier dysfunction induced by activated microglia in mouse brain microvascular endothelial cells. Journal of Pharmacological Sciences 2010; 112(2): 251–254. doi: 10.1254/jphs.09292sc

[39] Lad SP, Hegen H, Gupta G, et al. Proteomic biomarker discovery in cerebrospinal fluid for cerebral vasospasm following subarachnoid hemorrhage. Journal of Stroke and Cerebrovascular Diseases 2012; 21(1): 30–41. doi: 10.1016/j.jstrokecerebrovasdis.2010.04.004

[40] Wang JW, Gao JM, Huang YJ. Effects of puerarin on the vascular active factor related to cerebral vasospasm after aneurysm subarachnoid hemorrhage. Chinese Journal of Integrated Traditional and Western Medicine 2012; 32(2): 164–167.

[41] Aslam M, Ahmad N, Srivastava R, Hemmer B. TNF-alpha induced NFκB signaling and p65 (RelA) overexpression repress Cldn5 promoter in mouse brain endothelial cells. Cytokine 2012; 57(2): 269–275. doi: 10.1016/j.cyto.2011.10.016

[42] Goulay R, Flament J, Gauberti M, et al. Subarachnoid hemorrhage severely impairs brain parenchymal cerebrospinal fluid circulation in nonhuman primate. Stroke 2017; 48(8): 2301–2305. doi: 10.1161/STROKEAHA.117.017014

[43] Pluta RM, Bacher J, Skopets B, Hoffmann V. A non-human primate model of aneurismal subarachnoid hemorrhage (SAH). Translational Stroke Research 2014; 5(6): 681–691. doi: 10.1007/s12975-014-0371-9

[44] Luo C, Yao X, Li J, et al. Paravascular pathways contribute to vasculitis and neuroinflammation after subarachnoid hemorrhage independently of glymphatic control. Cell Death & Disease 2016; 7(3): e2160. doi: 10.1038/cddis.2016.63

[45] Lv T, Zhao B, Hu Q, Zhang X. The glymphatic system: A novel therapeutic target for stroke treatment. Frontiers in Aging Neuroscience 2021; 13: 689098. doi: 10.3389/fnagi.2021.689098

[46] Boluijt J, Meijers JCM, Rinkel GJE, Vergouwen MDI. Hemostasis and fibrinolysis in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: A systematic review. Journal of Cerebral Blood Flow & Metabolism 2015; 35(5): 724–733. doi: 10.1038/jcbfm.2015.13

[47] Ren Z, Iliff JJ, Yang L, et al. ‘Hit & run’ model of closed-skull traumatic brain injury (TBI) reveals complex patterns of post-traumatic AQP4 dysregulation. Journal of Cerebral Blood Flow & Metabolism 2013; 33(6): 834–845. doi: 10.1038/jcbfm.2013.30

[48] Liu E, Peng X, Ma H, et al. The involvement of aquaporin-4 in the interstitial fluid drainage impairment following subarachnoid hemorrhage. Frontiers in Aging Neuroscience 2021; 12: 611494. doi: 10.3389/fnagi.2020.611494

[49] Connolly ES, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. Stroke 2012; 43(6): 1711–1737. doi: 10.1161/STR.0b013e3182587839

[50] Dayyani M, Sadeghirad B, Grotta JC, et al. Prophylactic therapies for morbidity and mortality after aneurysmal subarachnoid hemorrhage: A systematic review and network meta-analysis of randomized trials. Stroke 2022; 53(6): 1993–2005. doi: 10.1161/STROKEAHA.121.035699

[51] Hong Y, He S, Zou Q, et al. Eupatilin alleviates inflammatory response after subarachnoid hemorrhage by inhibition of TLR4/MyD88/NF-κB axis. Journal of Biochemical and Molecular Toxicology 2023; 37(5): e23317. doi: 10.1002/jbt.23317

[52] Galea J, Ogungbenro K, Hulme S, et al. Reduction of inflammation after administration of interleukin-1 receptor antagonist following aneurysmal subarachnoid hemorrhage: Results of the subcutaneous interleukin-1Ra in SAH (SCIL-SAH) study. Journal of Neurosurgery 2018; 128(2): 515–523. doi: 10.3171/2016.9.JNS16615

[53] Zuo T, Gong B, Gao Y, Yuan L. An in vitro study on the stimulatory effects of extracellular glutamate on astrocytes. Molecular Biology Reports 2023; 50(8): 6611–6617. doi: 10.1007/s11033-023-08601-3

[54] Yang LY, Chen YR, Lee JE, et al. Dental pulp stem cell-derived conditioned medium alleviates subarachnoid hemorrhage-induced microcirculation impairment by promoting M2 microglia polarization and reducing astrocyte swelling. Translational Stroke Research 2022; 14(5): 688–703. doi: 10.1007/s12975-022-01083-8

[55] Chung C, Tsai H, Huang Y, et al. Attenuation in proinflammatory factors and reduction in neuronal cell apoptosis and cerebral vasospasm by minocycline during early phase after subarachnoid hemorrhage in the rat. BioMed Research International 2021; 2021: 5545727. doi: 10.1155/2021/5545727

[56] Jiang Y, Liu DW, Han XY, et al. Neuroprotective effects of anti-tumor necrosis factor-alpha antibody on apoptosis following subarachnoid hemorrhage in a rat model. Journal of Clinical Neuroscience 2012; 19(6): 866–872. doi: 10.1016/j.jocn.2011.08.038

[57] Maddahi A, Povlsen GK, Edvinsson L. Regulation of enhanced cerebrovascular expression of proinflammatory mediators in experimental subarachnoid hemorrhage via the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway. Journal of Neuroinflammation 2012; 9(1): 274. doi: 10.1186/1742-2094-9-274

[58] Sun X, Ji C, Hu T, et al. Tamoxifen as an effective neuroprotectant against early brain injury and learning deficits induced by subarachnoid hemorrhage: Possible involvement of inflammatory signaling. Journal of Neuroinflammation 2013; 10(1): 920. doi: 10.1186/1742-2094-10-157

[59] Wang Y, Zhou S, Han Z, et al. Fingolimod administration improves neurological functions of mice with subarachnoid hemorrhage. Neuroscience Letters 2020; 736: 135250. doi: 10.1016/j.neulet.2020.135250

[60] Xu H, Testai FD, Valyi-Nagy T, et al. VAP-1 blockade prevents subarachnoid hemorrhage-associated cerebrovascular dilating dysfunction via repression of a neutrophil recruitment-related mechanism. Brain Research 2015; 1603: 141–149. doi: 10.1016/j.brainres.2015.01.047

[61] Xu H, Pelligrino DA, Paisansathan C, Testai FD. Protective role of fingolimod (FTY720) in rats subjected to subarachnoid hemorrhage. Journal of Neuroinflammation. 2015; 12(1): 16. doi: 10.1186/s12974-015-0234-7.

[62] Chen J, Chen G, Li J, et al. Melatonin attenuates inflammatory response-induced brain edema in early brain injury following a subarachnoid hemorrhage: A possible role for the regulation of pro-inflammatory cytokines. Journal of Pineal Research 2014; 57(3): 340–347. doi: 10.1111/jpi.12173

[63] Lin CL, Dumont AS, Calisaneller T, et al. Monoclonal antibody against E selectin attenuates subarachnoid hemorrhage-induced cerebral vasospasm. Surgical Neurology 2005; 64(3): 201–205. doi: 10.1016/j.surneu.2005.04.038

[64] Pradilla G, Wang PP, Legnani FG, et al. Prevention of vasospasm by anti-CD11/CD18 monoclonal antibody therapy following subarachnoid hemorrhage in rabbits. Journal of Neurosurgery 2004; 101(1): 88–92. doi: 10.3171/jns.2004.101.1.0088

[65] Provencio JJ, Altay T, Smithason S, et al. Depletion of Ly6G/C+ cells ameliorates delayed cerebral vasospasm in subarachnoid hemorrhage. Journal of Neuroimmunology 2011; 232(1–2): 94–100. doi: 10.1016/j.jneuroim.2010.10.016

[66] Wu Y, Zhao X, Zhuang Z, et al. Peroxisome proliferator-activated receptor gamma agonist rosiglitazone attenuates oxyhemoglobin-induced toll-like receptor 4 expression in vascular smooth muscle cells. Brain Research 2010; 1322: 102–108. doi: 10.1016/j.brainres.2010.01.073

[67] Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25(2): 376–380. doi: 10.2337/diacare.25.2.376.

[68] Tosun C, Kurland DB, Mehta R, et al. Inhibition of the Sur1-Trpm4 channel reduces neuroinflammation and cognitive impairment in subarachnoid hemorrhage. Stroke 2013; 44(12): 3522–3528. doi: 10.1161/STROKEAHA.113.002904

[69] Shiokawa R, Otani N, Kajimoto R, et al. Glibenclamide attenuates brain edema associated with microglia activation after intracerebral hemorrhage. Neurochirurgie 2022; 68(6): 589–594. doi: 10.1016/j.neuchi.2022.07.009

[70] Simon M, Grote A. Interleukin 6 and aneurysmal subarachnoid hemorrhage: A narrative review. International Journal of Molecular Sciences 2021; 22(8): 4133. doi: 10.3390/ijms22084133